Medtronic EVP sells 1,483 shares at $93.65

Medtronic’s EVP & President Cardiovascular sold 1,483 shares and continues to hold 42,186 shares directly.

Rhea-AI Filing Summary

Medtronic plc (MDT) reported that Harry Skip Kiil, its EVP & President Cardiovascular, sold 1,483 Ordinary Shares on September 16, 2026 in an open-market or private transaction at a reported price of $93.65 per share. Following this sale, he directly holds 42,186 Ordinary Shares of Medtronic. The filing indicates no Rule 10b5-1 trading plan was affirmed for this transaction.

Insider Trade Summary

Net Seller: 1,483 shares

Net Sell 1 txn

Insider KIIL HARRY SKIP

Role EVP & President Cardiovascular

Sold 1,483 shs ($139K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,483	$93.65	$139K

Holdings After Transaction: Ordinary Shares — 42,186 shares (Direct)

Key Figures

Shares sold: 1,483 shares Sale price per share: $93.65 per share Post-transaction holdings: 42,186 shares

3 metrics

Shares sold 1,483 shares Ordinary Shares sold by Harry Skip Kiil on September 16, 2026

Sale price per share $93.65 per share Reported price for the 1,483 Ordinary Shares sold

Post-transaction holdings 42,186 shares Ordinary Shares directly held by Harry Skip Kiil after the sale

Key Terms

Ordinary Shares, open-market or private transaction, Rule 10b5-1 trading plan

3 terms

Ordinary Shares financial

"sold 1,483 Ordinary Shares on September 16, 2026"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open-market or private transaction financial

"Sale in open market or private transaction at $93.65 per share"

Rule 10b5-1 trading plan regulatory

"no Rule 10b5-1 trading plan was affirmed for this transaction"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medtronic plc (MDT) report for Harry Skip Kiil?

Medtronic reported that Harry Skip Kiil, EVP & President Cardiovascular, sold 1,483 Ordinary Shares on September 16, 2026 in a sale described as an open-market or private transaction, leaving him with 42,186 shares directly held afterward.

At what price were the Medtronic (MDT) shares sold by Harry Skip Kiil?

The reported sale by Harry Skip Kiil of Medtronic shares on September 16, 2026 was at a price of $93.65 per share, as disclosed for the 1,483 Ordinary Shares sold in the Form 4 filing.

How many Medtronic (MDT) shares does Harry Skip Kiil hold after the reported sale?

After selling 1,483 Ordinary Shares, Harry Skip Kiil directly holds 42,186 Ordinary Shares of Medtronic plc, according to the post-transaction holdings figure disclosed in the Form 4.

Was the Medtronic (MDT) insider sale by Harry Skip Kiil under a Rule 10b5-1 trading plan?

The Form 4 indicates that the Rule 10b5-1 checkbox was not affirmed, meaning the sale of 1,483 Medtronic Ordinary Shares by Harry Skip Kiil was not reported as being made under a Rule 10b5-1 trading plan.

What role does Harry Skip Kiil hold at Medtronic (MDT) in connection with this Form 4?

In this Form 4, Harry Skip Kiil is identified as an officer of Medtronic plc, serving as EVP & President Cardiovascular, and the filing reports his sale of 1,483 Medtronic Ordinary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:18 PM Accepted by SEC EDGAR 09/17/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIIL HARRY SKIP

(Last) (First) (Middle)

710 MEDTRONIC PARKWAY

(Street)

MINNEAPOLIS MINNESOTA 55432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medtronic plc [ MDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & President Cardiovascular

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/16/2026		S		1,483	D	$93.65	42,186	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Patricia Walesiewicz, attorney-in-fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)